Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

226.67 -5.11 (-2.20%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

October 26, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

OmniAb Business Combination Approved by APAC Shareholders

October 24, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

February 23, 2022

On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Earnings Scheduled For February 17, 2022 ↗

February 17, 2022

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

Via Benzinga

Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

October 03, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients ↗

August 25, 2022

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 24, 2022

Via Benzinga

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

August 24, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals...

Via Benzinga

Ligand Reports Second Quarter 2022 Financial Results

August 08, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 01, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report Second Quarter Financial Results on August 8

July 22, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗

July 05, 2022

Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%...

Via Benzinga

Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

June 29, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

10 Biggest Price Target Changes For Monday ↗

May 16, 2022

Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.

Via Benzinga

Ligand Reports First Quarter 2022 Financial Results

May 04, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report First Quarter Financial Results on May 4

April 19, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 08, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗

March 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger ↗

March 24, 2022

Ligand Pharmaceuticals Inc (NASDAQ: LGND)

Via Benzinga

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

March 23, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Tough Slogging Ahead for Investors, Diversification is Important ↗

March 07, 2022

Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.

Via Talk Markets

Recap: Ligand Pharmaceuticals Q4 Earnings ↗

February 17, 2022

Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Ligand Reports Fourth Quarter and Full Year 2021 Financial Results

February 17, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗

February 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

Ligand to Report Fourth Quarter Financial Results on February 17

February 09, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

December 22, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand and GSK Expand Global Collaboration and License Agreement

December 21, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.